TrialAdvances in therapy2026

Rocbrutinib, a Highly Selective Fourth-Generation Covalent and Noncovalent BTK Inhibitor, in R/R Non-GCB DLBCL: Efficacy and Safety from a Phase I Study.

Ningjing Lin et al.PubMed ↗Publisher ↗

No numbers read from the abstract.